TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Research Report·November 2, 2026

Twist Bioscience (TWST): AI Discovery and Margin Leverage

Twist Bioscience is posting strong revenue growth and improving margins, but valuation remains demanding. The stock earns a Hold as the company works toward adjusted EBITDA breakeven in fiscal Q4 2026.

Research ReportTWSTHealthcareBiotechnologyBiotech
By TickerSpark·November 2, 2026·16 min read

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Twist Bioscience (TWST): AI Discovery and Margin Leverage
C+
Overall
B-
Balance Sheet
C+
Income
B-
Estimates
D+
Valuation
TickerSpark AI RatingHold
▌Investment Summary
Twist Bioscience (TWST) is a Hold, earning an overall grade of C+, with a compelling growth story offset by demanding valuation and ongoing losses. Our fair value is $160, which reflects strong revenue momentum, improving gross margins, and the path to adjusted EBITDA breakeven without assuming flawless execution.

Thesis

Twist Bioscience (TWST) is a high-growth synthetic biology platform with a credible technology moat, improving gross margins, and a clear path toward adjusted EBITDA breakeven. The investment case rests on three facts: fiscal Q3 2026 revenue reached a record $118.4M, revenue grew 23.0% year over year for the 14th consecutive quarter, and management expects adjusted EBITDA breakeven in Q4 fiscal 2026.

The counterweight is valuation and execution risk. TWST carries a $10.1B market capitalization against $431.8M of reported revenue, an enterprise-value-to-revenue multiple of 23.3x, negative EBITDA, negative free cash flow, and a trailing EPS loss of $2.23. Analyst estimates place revenue at $548.6M in fiscal 2027, but EPS remains negative at $1.31 per share in that year and does not turn positive in the estimate set until fiscal 2030.

For a moderate-risk investor with a medium-term horizon, the appropriate stance is Hold. The company has the ingredients of a market leader, but the stock already prices in a large portion of the growth story. The central valuation anchor in this report is $160 per share, which recognizes TWST's growth platform without treating future profitability as a finished product.

Company Overview

Twist Bioscience manufactures synthetic DNA using a proprietary semiconductor-based platform. Its products serve therapeutic discovery, diagnostics, next-generation sequencing, industrial biology, agriculture, academic research, and data storage. The company was incorporated in 2013, went public on Nasdaq in 2018, and employed 979 people.

The business combines silicon-based DNA synthesis with proprietary software, automated manufacturing, an e-commerce platform, and commercial infrastructure. That combination allows TWST to sell more than a single laboratory product. It gives customers access to synthetic genes, oligo pools, DNA libraries, antibody discovery tools, protein solutions, and NGS workflow products.

▌Common Questions

Frequently asked questions

+Is TWST stock a buy right now?
TWST is not a Buy right now; it is a Hold. The company is growing quickly and expects adjusted EBITDA breakeven in Q4 fiscal 2026, but the stock already reflects a lot of that progress at a rich valuation.
+What is TWST's fair value?
TWST's fair value is $160. We arrive there by balancing the company's 23.0% year-over-year revenue growth, improving gross margin profile, and expected EBITDA breakeven against a still-negative earnings outlook and a 23.3x enterprise value-to-revenue multiple.
+Why is Twist Bioscience still rated Hold despite strong growth?
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

Chief Executive Officer and co-founder Emily Leproust leads the company alongside President and Chief Operating Officer Patrick Finn and Chief Financial Officer Adam Laponis. The 2025 10-K describes TWST as a company still building scale in a fast-moving and intensely competitive market. That description fits the financial profile: strong revenue expansion, improving gross margins, and continuing operating losses.

Business Segment Deep Dive

TWST reports two broad operating groups: DNA Synthesis and Protein Solutions, or DSPS, and NGS Applications. In fiscal Q3 2026, DSPS revenue reached $56.6M, up 39.0% year over year. NGS Applications revenue reached $61.8M, up 12.0% year over year and 8.0% sequentially.

The annual product mix shows NGS Tools as the largest product category in fiscal 2025 at $208.1M, or 55.3% of total revenue. Synthetic Genes contributed $113.6M, or 30.2%, while Antibody Discovery generated $23.5M, Oligo Pools produced $20.2M, and DNA and Biopharma Libraries added $11.2M.

The mix is moving toward higher-growth therapeutic and discovery applications. Fiscal Q3 2026 therapeutic revenue grew 49.0% to $40.4M, diagnostics revenue rose 15.0% to $43.8M, and academic and government revenue increased 32.0% to $15.5M. Industry and applied revenue was $5.7M, while global supply partner revenue was $12.9M and provided a stable recurring base.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

Flagship Product Analysis

The flagship product is the silicon-based DNA synthesis platform. It miniaturizes phosphoramidite chemistry on a semiconductor chip, reducing reagent consumption while increasing scale and throughput. The platform supports standard genes, complex genes, oligo pools, DNA libraries, protein expression, and antibody discovery workflows.

Complex Genes is an important proof point. During early access, customers ordered more than 1,800 complex genes across more than 100 orders. TWST completed the overwhelming majority of these constructs within 12 days and later expanded the offering across the broader market. These sequences contain demanding features such as high GC content and repetitive elements, so commercial production at scale is a meaningful technical test.

AI-enabled antibody discovery is the other flagship growth vector. Customers generate thousands or millions of digital sequences, then use TWST to synthesize DNA, express proteins, and test binding and developability. Management expects triple-digit order growth for AI-enabled discovery in fiscal 2026 and expects another triple-digit increase in fiscal 2027.

Innovation & Competitive Advantage

TWST's advantage is broader than its chip technology. Management describes a system that combines intellectual property, manufacturing, automation, software, product development, customer engagement, and commercial execution. Each additional product gives the same infrastructure more volume, while each customer adds data, workflow integration, and potential wallet share.

Operational figures support that claim. Over the last three years, TWST reduced manufacturing costs by 60.0%, reduced waste by 70.0%, reduced turnaround time by roughly 73.0%, and increased oligonucleotide capacity fourfold. Management also reports that 70.0% of incremental Q3 revenue reached the gross-margin line.

The business is becoming more embedded in customer research workflows. That matters because a laboratory customer buying one gene is a transaction, while a pharmaceutical company using TWST for repeated design, build, test, and learn cycles represents a broader relationship. The moat is real, but it still requires continued execution because competitors such as Danaher (DHR) through Integrated DNA Technologies, Thermo Fisher Scientific (TMO), Azenta (AZTA), and Illumina (ILMN) possess significant resources.

Operations & Supply Chain

TWST operates a manufacturing model built for automation and repeatability. In fiscal Q3 2026, the company shipped 369,000 genes. Its strategy is to move new products onto existing automated production lines rather than build a separate process for every customer. Complex Genes demonstrates that approach by using the same manufacturing infrastructure as standard and express gene production.

Gross margin reached 52.8% in fiscal Q3 2026, up 120 basis points sequentially. Management expects fiscal 2026 gross margin above 52.0% and has set a long-term goal above 60.0% as the business matures. Capital expenditures were $9.7M in the quarter and $28.0M for fiscal 2025, reflecting the investment needed to expand production capacity.

The 2025 10-K identifies supply-chain exposure, including dependence on one supplier for a critical component and sensitivity to trade-policy disruptions. TWST is also developing proprietary enzymes for internal workflows. That effort is designed to improve performance and cost while reducing supplier dependence.

Market Analysis

TWST operates at the intersection of synthetic biology, genomics, antibody discovery, and NGS sample preparation. Management estimates a $13B serviceable addressable market by 2030. The company also cites a $6B serviceable addressable market for NGS Applications and a $7B-plus serviceable addressable market for DNA Synthesis and Protein Solutions.

External market research points to strong structural demand. Mordor Intelligence estimates the broader biotechnology market at $2.42T in 2026 and $4.91T by 2032, while MarketsandMarkets estimates the global biotech industry at $546.0B in 2025. The wide gap reflects different market definitions, but both figures capture the same commercial reality: biotechnology is expanding across therapeutics, diagnostics, agriculture, industrial applications, and research.

Sequencing, bioinformatics, AI-assisted discovery, and personalized medicine create direct demand for TWST's products. Management's Q3 results show that demand reaching the income statement through 49.0% therapeutic growth, 15.0% diagnostics growth, and 32.0% academic and government growth.

Like what you're reading?

Get full access to AI-powered research reports, market analysis, and portfolio tools.

Get Started →

Customer Profile

TWST serves large pharmaceutical companies, dry-lab biotechnology firms, traditional biotechnology companies, technology companies entering life sciences, diagnostics developers, agricultural biotech companies, academic laboratories, government institutions, and global supply partners.

The customer base combines recurring research demand with commercial adoption opportunities. In fiscal Q3 2026, TWST served 657 NGS Applications customers, with 182 adopting its products. The top 10 NGS customers represented approximately 48.0% of NGS Applications revenue, creating concentration risk but also showing meaningful account depth.

The strongest customer economics come from programs that repeatedly cycle through design, synthesis, expression, and testing. AI-enabled antibody discovery fits that pattern. Diagnostics customers also create attractive volume potential as assays move from development toward commercialization. Academic and government demand adds breadth, although order patterns in that group can fluctuate.

Competitive Landscape

TWST competes in core DNA synthesis with Integrated DNA Technologies, GenScript, Thermo Fisher's GeneArt, Azenta's GENEWIZ, Eurofins Genomics, ATUM, DNA Script, Elegen, Ansa Biotechnologies, and Telesis Bio. In NGS sample preparation and target enrichment, the competitive set includes Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Roche, and New England Biolabs.

The competitive battleground is defined by price, accuracy, quality, turnaround time, product breadth, throughput, scale, and technical support. TWST's silicon platform gives it a differentiated cost and throughput proposition, while its e-commerce and API capabilities improve workflow integration.

The risk is that a technology advantage becomes less distinctive as alternatives improve. TWST must continue converting manufacturing gains into lower costs, faster delivery, and better product quality. The company is competing against both established life-science suppliers and venture-backed firms pursuing new DNA synthesis methods.

Macro & Geopolitical Landscape

The macro backdrop is favorable for companies that reduce the time and cost of biological research. AI is moving into drug discovery workflows, while sequencing, precision medicine, and biologics continue to expand. TWST's Q3 transcript recorded greater adoption of AI as an initial antibody discovery screen across large pharma, biotech, and technology companies.

Geographic demand is broad. Fiscal Q3 2026 revenue grew 30.0% in the Americas to $77.3M, 9.0% in EMEA to $33.6M, and 26.0% in APAC to $7.5M. External market research places Asia-Pacific biotechnology growth at 16.4% annually through 2032, which gives TWST a meaningful regional expansion opportunity.

The main external risks are trade restrictions, regulatory changes, research-budget volatility, and a slowdown in biotech financing. The 2025 10-K also highlights intellectual-property protection, rapid technological change, and international regulatory exposure. These risks matter more for TWST because the company is still investing heavily while it works toward sustained profitability.

Balance Sheet Health

▌Premium Members Only

TWST's balance sheet earns a B- as the company supports growth with a manageable capital structure, but it still has to prove it can convert scale into durable cash generation.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Income Statement Strength

▌Premium Members Only

Fiscal Q3 2026 revenue hit a record $118.4M and rose 23.0% year over year for the 14th straight quarter, yet the company still posted negative EBITDA and a trailing EPS loss of $2.23.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Estimates Outlook

▌Premium Members Only

Analysts see revenue rising to $548.6M in fiscal 2027, but EPS is still expected to be negative at $1.31 per share that year and not turn positive until fiscal 2030.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Valuation Assessment

▌Premium Members Only

At a $10.1B market cap and 23.3x enterprise value to revenue, TWST trades at a premium that leaves little room for execution missteps despite its growth profile.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Target Prices & Recommendation

▌Premium Members Only

The report's central valuation anchor is $160 per share, which sits between the bullish and bearish scenarios and supports a Hold stance for moderate-risk investors.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Closing

Twist Bioscience has built a differentiated platform in a market where speed, scale, precision, and automation matter. Fiscal Q3 2026 provided meaningful evidence of progress: revenue grew 23.0%, gross margin reached 52.8%, therapeutic revenue grew 49.0%, and management raised fiscal 2026 revenue guidance to $456M to $457M.

The investment remains a transition story. TWST must convert revenue growth into sustained EBITDA, GAAP earnings, and positive free cash flow. Its cash position and low debt provide operating room, but a 23.3x enterprise-value-to-revenue multiple leaves the stock sensitive to any slowdown in AI-enabled discovery, diagnostics adoption, or margin expansion.

For a medium-term, moderate-risk portfolio, Hold is the disciplined choice. The business deserves continued attention because its technology and customer adoption are improving, but the entry point becomes more compelling at $135 or below, where the valuation would better compensate investors for the remaining path to profitability.

Twist Bioscience is rated Hold because the growth is real, but profitability is still ahead of the business and the valuation is already elevated. Revenue reached $118.4M in fiscal Q3 2026, yet the company still posted negative EBITDA and a trailing EPS loss of $2.23.
+What are the biggest catalysts for TWST stock?
The biggest catalysts are continued growth in AI-enabled antibody discovery, expansion in therapeutic revenue, and the move to adjusted EBITDA breakeven in Q4 fiscal 2026. Management also expects triple-digit order growth in AI-enabled discovery in fiscal 2026 and again in fiscal 2027.
+What is the main risk with TWST shares?
The main risk is that execution has to stay strong while the stock trades at a premium valuation. TWST still has negative free cash flow and earnings are not expected to turn positive until fiscal 2030 in the current estimate set.
▌For Active Investors

Want Reports Like This on Any Stock?

Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More on TWST

More to read

All articles
Imperium, Revealed: What Stock Is Adam O’Dell Teasing in Green Zone Fortunes?
TWST

Imperium, Revealed: What Stock Is Adam O’Dell Teasing in Green Zone Fortunes?

Adam O’Dell and Money & Markets are pushing Imperium, the Green Zone Fortunes pitch built around the DNA revolution. We identify the company behind it and test the claims.

Nov 13·10 min
Twist Bioscience Corporation (TWST) drops on deep earnings beat
TWST

Twist Bioscience Corporation (TWST) drops on deep earnings beat

Twist Bioscience Corporation (TWST) beat earnings and revenue estimates, yet the stock drops as investors weigh valuation, margin progress and growth expectations. This deep-dive examines the company’s 15th straight quarter of sequential revenue growth, AI drug discovery momentum, NGS expansion and the path toward sustained profitability.

Nov 12·6 min
Twist Bioscience Corporation (TWST) falls on earnings beats
TWST

Twist Bioscience Corporation (TWST) falls on earnings beats

Twist Bioscience Corporation (TWST) falls after earnings beats, with shares down 12.0% as investors react to the latest quarterly results and outlook.

Nov 12·2 min